Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT DERM versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT DERM versus NYSTEX.
MONISTAT-DERM vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole inhibits fungal lanosterol 14α-demethylase, a cytochrome P450 enzyme, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
Topical: Apply once daily to affected areas for 2-4 weeks. Vaginal: One 200 mg suppository at bedtime for 3 days, or one 100 mg suppository at bedtime for 7 days, or one 1200 mg suppository as a single dose.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 24–30 hours, supporting twice-daily or once-daily dosing for dermatologic infections.
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Primarily fecal (biliary) elimination as unchanged drug and metabolites; <1% renal excretion of unchanged drug.
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal